Skip to content
Jack Core Direct

{‘She possesses little qualifications’: the American healthcare community girds for Høeg's role at the FDA.

While America proceeds with sweeping revisions to its vaccination schedules, a particular individual has emerged in a surprising turn: Høeg, an American of Danish descent physician and public health researcher who first made her name by expressing skepticism about COVID-19 vaccines in the global health crisis and has focused upon potential fatalities after COVID-19 vaccination in her recent position at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Program

Health officials had intended to reveal radical changes to the childhood immunization program recently, bringing the US with Denmark’s national calendar, sources say – a significant shift that would put the US out of step with much of the world with insufficient data for improved outcomes. The planned update has been postponed until the new year.

Rather than the director of the vaccine center, Høeg is scheduled to present at the gathering. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to lead the division this calendar year.

A Shift at the Regulatory Body

This interim role could signify a closer partnership between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a greater focus upon dismantling already-approved vaccines at the FDA.

The new acting director has frequently advocated for halting specific childhood immunization guidelines in the US in order to be more similar to Denmark, a nation with nationalized medicine and a population about the size of the state of Wisconsin.

In her initial public appearances, she has kept her attention on immunizations – traditionally the purview of Dr. Prasad, head of the FDA’s CBER – rather than drug regulation.

Doubts Over Background

Dr. Høeg has little discernible background in pharmaceutical research, oversight or leadership, which has been customary for past heads of the CBER. She has served at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in running a large organization. She lacks background in industry regulation.”

Previous directors of the center would “grasp legal statutes and the research of medication creation”, commented Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who headed CBER have had.”

The drug center has an vast range of responsibilities at the agency, the former commissioner pointed out.

“Many people just zeroes in on the innovative therapies, but the off-patent medication office clears thousands of off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and other areas, and every single one must be looked after,” she said. “The thing you overlook, that is the part that I always told people is going to come back to haunt you.”

There is also, a major leadership aspect to the job, which supervises over 5,000 personnel. “It is a huge leadership role, if you perform it correctly,” the former official added.

Response and Disputed Initiatives

In response to inquiries about Høeg’s qualifications and whether this selection signifies greater collaboration among regulatory chiefs on vaccines, a representative responded that the “questions are based on inaccurate premises”.

“This background aligns with the duties of her position,” the representative explained, noting the months Høeg spent guiding the agency head on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg takes over the agency head's new fast-track approval initiative, a disputed expedited therapy clearance system that reportedly troubled her predecessors. “By what process are these medications being chosen for this voucher program? Who is making the choices?” Howard questioned. “There is a lot of confidentiality occurring at the agency right now.”

Broadly speaking, he stated, “the FDA looks to be trending towards more relaxed oversight of pharmaceuticals, aside from vaccines.”

Established History on Vaccines

Concerning immunizations, Høeg has a more documented, if troubling, history, Howard have noted. She released a study using unconfirmed public submissions to estimate the rate of myocarditis after Covid vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to imply Covid vaccinations are more dangerous than they are.

Included in her “policy goals” for the incoming government encompassed changing rules for recently developed shots and ending “optional” immunizations, she remarked post-election on a audio program. At the agency, Dr. Høeg has allegedly suggested barring teenage boys from receiving Covid vaccinations.

“She’s an thorough true believer who starts off with her preconceived notions and works backwards to retrofit the data in a very misleading, untruthful way,” Dr. Howard stated.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow skeptics, {like|

AJ
About the author

Alejandro Jones

A tech enthusiast and product reviewer with over a decade of experience in consumer electronics and software development.

Jack Core Direct

Type to search articles.